Result of AGM

Diaceutics PLC

25 June 2026

 

Diaceutics PLC - Results of AGM

New York, Belfast and London, 25 June 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed. The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

Resolution		For (excluding at Chair's discretion)		Against		Total votes cast	Withheld
		Number of votes	%	Number of votes	%	Number of votes	Number of votes
1	Ordinary resolution to receive To receive and consider the Company's financial statements for the financial year ended 31 December 2025 together with the directors' report and the auditors' report on those annual accounts	53,917,796	99.99	7,000	0.01	53,924,796	207
2	Ordinary resolution to approve the directors' remuneration report	52,481,617	97.33	1,441,199	2.67	53,922,816	2,187
3	Ordinary resolution to re-elect Graham Paterson as a director of the Company	48,829,837	93.02	3,662,479	6.98	52,492,316	1,432,687
4	Ordinary resolution to re-elect Peter Keeling as a director of the Company	46,579,688	86.38	7,343,128	13.62	53,922,816	2,187
5	Ordinary resolution to re-elect Ryan Keeling as a director of the Company	51,859,014	96.17	2,063,802	3.83	53,922,816	2,187
6	Ordinary resolution to re-elect Nick Roberts as a director of the Company	51,859,014	96.17	2,063,711	3.83	53,922,725	2,278
7	Ordinary resolution to re-elect Jordan Clark as a director of the Company	51,859,014	96.17	2,063,711	3.83	53,922,725	2,278
8	Ordinary resolution to re-elect Cheryl MacDiarmid as a director of the Company	53,501,672	99.22	421,053	0.78	53,922,725	2,278
9	Ordinary resolution to re-appoint Ernst & Young as auditors of the Company	53,878,631	99.92	44,186	0.08	53,922,817	2,186
10	Ordinary resolution to authorise the directors to determine the remuneration of the auditors	53,912,118	99.98	10,699	0.02	53,922,817	2,186
11	Ordinary resolution to authorise the directors to allot ordinary shares	53,915,269	99.99	7,213	0.01	53,922,482	2,521
12	Special resolution to authorise the directors to dis-apply statutory pre-emption rights pursuant to section 570 of the Companies Act 2006	53,895,048	99.96	23,948	0.04	53,918,996	6,007
13	Special resolution to authorise the directors to make market purchase of its ordinary shares	51,491,743	99.99	6,099	0.01	51,497,842	2,427,161

Enquiries: 

Diaceutics PLC
Ryan Keeling, Chief Executive Officer   Nick Roberts, Chief Financial Officer	Tel: [phone] [e-mail]
Canaccord Genuity Limited (Nomad & Broker)	Tel: [phone]
Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

END